ReviewVirulence2017
Antifungal adjuvants: Preserving and extending the antifungal arsenal.
Review in Virulence, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Antimicrobial Resistance and the Blood-Brain Barrier: Complex Interactions and Implications for Neurological Health.Molecular neurobiology · 2025Review
- Genome-Wide DNA Changes Acquired byMicroorganisms · 2023Article
- A host defense peptide mimetic, brilacidin, potentiates caspofungin antifungal activity against human pathogenic fungi.Nature communications · 2023Article
- New perspectives on the topical management of recurrent candidiasis.Drug delivery and translational research · 2021Review
- The role of aneuploidy in the emergence of echinocandin resistance in human fungal pathogen Candida albicans.PLoS pathogens · 2021Article
- Current and promising pharmacotherapeutic options for candidiasis.Expert opinion on pharmacotherapy · 2021Article
- Combining Colistin and Fluconazole Synergistically Increases Fungal Membrane Permeability and Antifungal Cidality.ACS infectious diseases · 2021Article
- The Antifungal Activity of HMA, an Amiloride Analog and Inhibitor of NaFrontiers in microbiology · 2021Article
- Antifungal Drug Repurposing.Antibiotics (Basel, Switzerland) · 2020Article
- Review
- Article
- Antifungal In Vitro Activity of Pilosulin- and Ponericin-Like Peptides from the Giant AntAntibiotics (Basel, Switzerland) · 2020Article
- Article
- Phosphate is the third nutrient monitored by TOR inProceedings of the National Academy of Sciences of the United States of America · 2017Article
- The unmet clinical need of novel antifungal drugs.Virulence · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
As the rates of systemic fungal infections continue to rise and antifungal drug resistance becomes more prevalent, there is an urgent need for new therapeutic options. This issue is exacerbated by the limited number of systemic antifungal drug classes. However, the discovery, development, and approval of novel antifungals is an extensive process that often takes decades. For this reason, there is growing interest and research into the possibility of combining existing therapies with various adjuvants that either enhance activity or overcome existing mechanisms of resistance. Reports of antifungal adjuvants range from plant extracts to repurposed compounds, to synthetic peptides. This approach would potentially prolong the utility of currently approved antifungals and mitigate the ongoing development of resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.